Citius Oncology Files 8-K: Material Agreement and Other Events
Ticker: CTOR · Form: 8-K · Filed: Jul 18, 2025 · CIK: 1851484
| Field | Detail |
|---|---|
| Company | Citius Oncology, INC. (CTOR) |
| Form Type | 8-K |
| Filed Date | Jul 18, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, filing, financials
TL;DR
Citius Oncology signed a big deal & filed docs on 7/16. Check it out!
AI Summary
On July 16, 2025, Citius Oncology, Inc. entered into a material definitive agreement. The company also reported on other events and filed financial statements and exhibits. The filing was made on July 18, 2025.
Why It Matters
This 8-K filing indicates significant corporate activity for Citius Oncology, including a new material agreement and the submission of financial documents, which could impact investors' understanding of the company's current status and future prospects.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement, which could represent significant opportunities or risks for the company, but the specifics are not detailed in this summary.
Key Numbers
- 001-41534 — SEC File Number (Identifies the company's filing history with the SEC.)
- 0930 — Fiscal Year End (Indicates the end of the company's financial reporting year.)
Key Players & Entities
- CITIUS ONCOLOGY, INC. (company) — Registrant
- July 16, 2025 (date) — Date of earliest event reported
- July 18, 2025 (date) — Filing date
- 11 Commerce Drive, 1st Floor, Cranford, NJ 07016 (address) — Principal executive offices
- TenX Keane Acquisition (company) — Former company name
FAQ
What is the nature of the material definitive agreement entered into by Citius Oncology?
The filing states that Citius Oncology, Inc. entered into a 'Material Definitive Agreement' on July 16, 2025, but the specific details of this agreement are not provided in the provided text.
What other items are reported in this 8-K filing?
Besides the material definitive agreement, the filing also reports on 'Other Events' and 'Financial Statements and Exhibits'.
When was this 8-K form filed with the SEC?
This 8-K form was filed with the SEC on July 18, 2025.
What was Citius Oncology, Inc. formerly known as?
Citius Oncology, Inc. was formerly known as TenX Keane Acquisition, with a date of name change on March 15, 2021.
Where are Citius Oncology's principal executive offices located?
Citius Oncology's principal executive offices are located at 11 Commerce Drive, 1st Floor, Cranford, NJ 07016.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 18, 2025 regarding CITIUS ONCOLOGY, INC. (CTOR).